Prevalence of non-pneumonic infections with SARS-correlated virus.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups.Epidemiology and infection · 2006
   Pooled it
2. Coronavirus Disease 2019: Coronaviruses and Blood Safety.Transfusion medicine reviews · 2020
   Review
3. Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates.Transfusion medicine (Oxford, England) · 2005
   Article
4. Evaluation of inapparent nosocomial severe acute respiratory syndrome coronavirus infection in Vietnam by use of highly specific recombinant truncated nucleocapsid protein-based enzyme-linked immunosorbent assay.Clinical and diagnostic laboratory immunology · 2005
   Article

Corrections and comments

• Comment on
  Relative rates of non-pneumonic SARS coronavirus infection and SARS coronavirus pneumonia.2004

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as